D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

The Greater Middle East is home to a rich genetic diversity that remains largely untapped in genomic research. This Perspective explores its potential for rare disease research, obstacles limiting ...

Our study disproves this hypothesis and we demonstrate that although cell–cell contact is needed, a specific molecule does not need a corresponding receptor on another cell to be trogocytosed.

"For example, we believe that oligonucleotide drugs will become one of the modalities capable of targeting diseases that could not be treated by small molecule drugs," says Mr. Fujie. "We have ...

An office space in a place of work is important because it offers space for productivity, collective innovation, and the well-being of employees. Most contemporary workspaces are furnished with ...

An artificial intelligence model has created a new protein that researchers say would have taken 500 million years to evolve in nature — if nature were capable of producing such a thing.

Officially, the Pixel 9 is “twice as durable as Pixel 8,” with Google crediting the new design language. A new blog post from the company this week discusses the internal testing process.

The drug restored the cholinergic system and improved memory,” added Moreno. Rafael Rodríguez believes that “this molecule could become a drug to treat the symptoms of dementia, at least during the ...

With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth.